Health Affairs, 26, no. 1 (2007): 62-74 doi: 10.1377/hlthaff.26.1.62 © 2007 by Project HOPE	New Online   How Would Obama, McCain Cover The Uninsured?   Debating Cost Of Uninsured   Try Medicare-For-All   HA Blog Top 10

This Article Figures Only Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Califf, R. M. Articles by Schulman, K. A. Search for Related Content PubMed PubMed Citation Articles by Califf, R. M. Articles by Schulman, K. A. Related Collections Cardiovascular Disease Chronic Care Consumer Issues Health Promotion/Disease Prevention Public Health Research And Technology

Quality

Curbing The Cardiovascular Disease Epidemic: Aligning Industry, Government, Payers, And Academics

Despite decades of progress in the diagnosis, treatment, and prevention of cardiovascular disease, its prevalence continues to grow in both developed and developing countries. We have constructed a model, the "cycle of quality," which connects the innovation of initial scientific discovery with validated methods of translating research into effective delivery. This model can serve as a basis for evaluating proposed efforts to improve interactions among private and public aspects of health care to accelerate development and appropriate adoption of new treatments, and to achieve greater penetration of effective behavioral therapies and established technologies, resulting in major improvements in cardiovascular health.

                      What's this?

This article has been cited by other articles:

				R. Peto, J. Emberson, M. Landray, C. Baigent, R. Collins, R. Clare, and R. Califf Analyses of Cancer Data from Three Ezetimibe Trials N. Engl. J. Med., September 2, 2008; (2008) NEJMsa0806603v1. [Abstract] [Full Text] [PDF]

				J. Himmelfarb Chronic Kidney Disease and the Public Health: Gaps in Evidence From Interventional Trials JAMA, June 20, 2007; 297(23): 2630 - 2633. [Full Text] [PDF]

				R. M. Califf The cycle of quality as a model for improving health outcomes in the treatment of hypertension Eur. Heart J. Suppl., May 1, 2007; 9(suppl_B): B8 - B12. [Abstract] [Full Text] [PDF]

				E. L. Eisenstein, D. F. Kong, K. J. Anstrom, and R. M. Califf Clopidogrel and Long-term Outcomes After Drug-Eluting Stent Implantation--Reply JAMA, April 25, 2007; 297(16): 1770 - 1771. [Full Text] [PDF]

				K. W. Mahaffey and R. A. Harrington Optimal Timing for Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes: Questions, Answers, and More Questions JAMA, February 14, 2007; 297(6): 636 - 639. [Full Text] [PDF]